Clinical Trials Logo

Recurrence clinical trials

View clinical trials related to Recurrence.

Filter by:

NCT ID: NCT01479244 Completed - Clinical trials for Breast Cancer With Low to Intermediate HER2 Expression

Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

PRESENT
Start date: November 2011
Phase: Phase 3
Study type: Interventional

Purpose of this trial: 1. To assess the efficacy and safety of NeuVax™ administered with adjuvant Leukine® (sargramostim, GM-CSF). 2. To evaluate and compare the disease free survival (DFS) in the vaccinated and control subjects.

NCT ID: NCT01463891 Completed - Clinical trials for Inoperable or Recurrent Breast Cancer

Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

Start date: July 19, 2011
Phase:
Study type: Observational

To investigate of the clinical safety and effectiveness of eribulin mesylate in patients with inoperable or recurrent breast cancer

NCT ID: NCT01450488 Completed - Multiple Sclerosis Clinical Trials

Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis

Start date: June 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the activity of oral AB1010, administered at two dose levels during 3 years to patients with primary or secondary progressive multiple sclerosis.

NCT ID: NCT01449877 Completed - Clinical trials for Ocular Toxoplasmosis

Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis

ISROT
Start date: October 2011
Phase: Phase 3
Study type: Interventional

The investigators study aims to determine the effect of prophylactic therapy with Trimethoprim-sulfamethoxazole on the recurrences of toxoplasma retinochoroiditis gondii. This is a randomized, double-masked, in patients with eye condition of acute Toxoplasma gondii retinochoroiditis. Volunteers will be recruited with a previous diagnosis of chorioretinitis presumed Toxoplasma gondii, which show active lesions compatible with recurrence. After the acute phase of treatment of all patients [1 tablet Trimethoprim-sulfamethoxazole (800/160mg) 12/12h during 45 days], the same Stratified by gender) will be randomized in a 1:1 ratio between the group 1 - TMP-SMZ (prophylactic treatment with trimethoprim-sulfamethoxazole 1 tablet every other day for 311 days) or group 2 - placebo (consisting of a placebo pill containing no active ingredient of similar appearance to trimethoprim-sulfamethoxazole, 1 tablet every other day for 311 days). The primary outcomes are incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 12, 36, 48, 60, 72, 84, 96, 108, and 120 months. Patients will be followed during the ten years in uveitis clinic at intervals defined as follows: return weekly for 4 weeks, then monthly for 2 months, then each 3 months for 9 months, and finally annually for 10 years.

NCT ID: NCT01447667 Completed - Clinical trials for Hepatocellular Carcinoma

Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)

MRE
Start date: October 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to determine: - The efficacy of MRE score as a predictor of HCC recurrence within 2 years after RFA treatment - The efficacy of each indicator (MRE score, non-invasive serum markers) compared to the gold-standard histology score predicting hepatic fibrosis

NCT ID: NCT01433497 Completed - Clinical trials for Multiple Sclerosis, Secondary Progressive

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

Start date: August 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of masitinib 6 mg/kg/day versus placebo in the treatment of patients with primary progressive multiple sclerosis or relapse-free secondary progressive multiple sclerosis.

NCT ID: NCT01431209 Completed - Clinical trials for Refractory Diffuse Large B-Cell Lymphoma

Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant

Start date: August 12, 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ruxolitinib phosphate works in treating patients with diffuse large B-cell or peripheral T-cell non-Hodgkin lymphoma that has returned (relapsed) or that does not respond to treatment (refractory) after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01420757 Completed - Postoperative Pain Clinical Trials

Laparoscopic Versus Open Incisional Hernia Repair

COLIBRI
Start date: May 1999
Phase: Phase 3
Study type: Interventional

Primary closure of incisional hernia without the use of a mesh shows recurrence rates of up to 54%. If a mesh is used, the defect can be closed tension-free. Using this method, recurrence rates have been reduced to 8-21%. Laparoscopic correction of incisional hernia is a relatively new technique in which the mesh is positioned intraperitoneally. Research has shown that this procedure is technical feasible and may have benefits for the patients. The ongoing debate about the merits of endoscopic versus open incisional hernia repair prompts the need for a level 1 randomized controlled trial.

NCT ID: NCT01384513 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Start date: August 4, 2011
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to compare the survival rates of patients with better risk disease undergoing hematopoietic stem cell transplant (HSCT) to the survival rates reported in the medical literature of similar patients undergoing reduced intensity HSCT from matched related donors.

NCT ID: NCT01378338 Completed - Clinical trials for The Aim of This Study is to Investigate the Frequency and Related Risk Factors of Recurrence, and Quality of Life in Patients With GERD After Treatment With PPI

Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational

Refresh
Start date: June 2012
Phase: N/A
Study type: Observational

Recurrence rate, risk factors for the recurrence, and quality of life in patients with GERD in Korea-an observational study.